2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Case Reports and Technical Notes
2014
Iron-Refractory Iron Deficiency Anemia (IRIDA)
Heeney MM, Finberg KE. Iron-Refractory Iron Deficiency Anemia (IRIDA). Hematology/Oncology Clinics Of North America 2014, 28: 637-652. PMID: 25064705, DOI: 10.1016/j.hoc.2014.04.009.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIron deficiency anemiaIron-refractory iron deficiency anemiaDeficiency anemiaChronic blood lossOral iron supplementationParenteral iron therapyInadequate dietary intakeSingle clinical entitySystemic iron homeostasisIron therapyBlood lossClinical featuresClinical entityIron supplementationDietary intakeAnemiaMultiple family membersCommon global problemTMPRSS6 geneRecent genetic studiesFamily membersIron homeostasisEtiologyTherapyIntake